CHARLOTTE, N.C. / Jan 16, 2024 / Business Wire / Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2024 second quarter on Tuesday, February 6, 2024, at approximately 6:30 a.m. ET. The company will also host a conference call at 8:00 a.m. ET to discuss its financial results.
The live webcast and replay will be available in the Investor Relations section of the company’s website at Events & Presentations. The webcast should be accessed 10 minutes prior to the conference call start time. The replay of the event will be available for one year following the conclusion of the live broadcast.
For those parties who do not have internet access, the conference call can be accessed by calling one of the below telephone numbers and asking to join the Premier, Inc. call:
Domestic participant dial-in number (toll-free): | (833) 953-2438 |
International participant dial-in number: | (412) 317-5767 |
About Premier, Inc.
Premier, Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,350 U.S. hospitals and health systems and approximately 300,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com, as well as X, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.
Last Trade: | US$21.19 |
Daily Change: | -0.01 -0.05 |
Daily Volume: | 140,367 |
Market Cap: | US$2.040B |
December 03, 2024 November 05, 2024 August 19, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB